Format

Send to

Choose Destination
Int J Cardiol. 2018 Nov 1;270:245-252. doi: 10.1016/j.ijcard.2018.05.087. Epub 2018 May 26.

The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.

Author information

1
Liver Center, Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, United States; Harvard Medical School, Boston, MA, United States.
2
Harvard Medical School, Boston, MA, United States; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, United States.
3
Duke Clinical Research Institute, Durham, NC, United States.
4
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, United States.
5
Harvard Medical School, Boston, MA, United States; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, United States. Electronic address: rgiugliano@partners.org.

Abstract

OBJECTIVE:

The nonalcoholic fatty liver disease fibrosis score (NFS) is comprised of unique metabolic risk indicators that may accurately predict residual cardiovascular (CV) risk in patients with established coronary disease and metabolic dysfunction.

METHODS:

We applied the NFS prospectively to 14,819 post-ACS patients randomized to ezetimibe/simvastatin (E/S) or placebo/simvastatin (P/S), in the IMPROVE-IT trial, using validated NFS cutoffs. The primary endpoint included CV death, myocardial infarction, unstable angina, revascularization or stroke. Outcomes were compared between NFS categories and treatment arms using frequency of events, KM rates and adjusted Cox proportional hazard models. The ability of the NFS to predict recurrent CV events was independently validated in 5395 placebo-treated patients enrolled in the SOLID-TIMI 52 trial.

RESULTS:

Among 14,819 patients enrolled in IMPROVE-IT, 14.2% (N = 2106) were high-risk (NFS > 0.67). The high-risk group had a 30% increased risk of recurrent major CV events, compared to the low-risk NFS group (HR 1.30 [1.19-1.43]; p < 0.001). Among high-risk patients, ezetimibe/simvastatin conferred a 3.7% absolute reduction in risk of recurrent CV events, compared to placebo/simvastatin (HR 0.85 [0.74-0.98]), translating to a number-needed-to-treat of 27. Similar benefit was not found in the low-risk group (HR ezetimibe/simvastatin vs. placebo/simvastatin, 1.01 [0.91-1.12]; p-interaction = 0.053). The relationship between NFS category and recurrent CV events was independently validated in patients enrolled in SOLID-TIMI 52 (HR for NFS > 0.67 vs. NFS < -1.455 = 1.55 [1.32-1.81]; p < 0.001).

CONCLUSION:

Stratification of cardiovascular risk by NFS identifies an independent population of patients who are at highest risk of recurrent events, and most likely to benefit from dual lipid-lowering therapy. Clinical trials.gov: NCT00202878.

KEYWORDS:

Acute coronary syndrome; Cardiovascular disease; Ezetimibe; Fatty liver; Low-density lipoprotein cholesterol; Metabolic syndrome; NAFLD; Statin

PMID:
29903515
PMCID:
PMC6139264
[Available on 2019-11-01]
DOI:
10.1016/j.ijcard.2018.05.087
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center